while the fda isn ’ t obliged to follow recommendations of advisers , their support eases concern that had caused orexigen shares to drop more than a third this year . newline_char “ the fact that they were able to convince the panel not only that the cardiovascular study can wait , but that the drug can be approved , is exciting , particularly after we saw the other obesity drugs voted down , ” joshua schimmer , a leerink swann analyst , said yesterday in a telephone interview . newline_char the la jolla , california-based company gained from watching the fda ’ s safety focus and saw  newline_char outside advisers to the food and drug administration said weight-loss benefits of orexigen ’ s product , contrave , exceed the dangers of elevated pulse and blood pressure and that a large study on cardiovascular risk can wait until after the drug is approved . story_separator_special_tag -- an fda advisory committee has voted 13-7 that the modest weight-loss benefits of an investigational combination of naltrexone and bupropion ( contrave ) outweigh the drug 's blood pressure risk . newline_char the bupropion naltrexone combo is the last in a trio of new weight-loss drugs that went before fda panels this year , striving to be the latest treatment in the dwindling field of medications to fight obesity . newline_char the previous two drugs , phentermine/topiramate ( qnexa ) and lorcaserin hydrochloride ( lorqess ) were both rejected by the fda after they fared poorly at advisory committee meetings . newline_char orexigen , the company that makes naltrexone/bupropion in partnership with takeda , is seeking approval for treatment of obesity and weight management in patients with a body mass index of 30 or above , or 27 or above and with one or more risk factors ( e.g.
